3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Phase 1/2
1
Status
Active not recruiting
2
Terminated
1
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
1
Study Type
Interventional
4
Sponsor
Cancer Type
Thoracic
4
Conditions
Triple Negative Breast Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Transitional Cell
3
Neoplasm Metastasis
2
Urinary Bladder Neoplasms
1
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma
1
Prostatic Neoplasms
1
Muscle Invasive Bladder Urothelial Carcinoma
1
Lung Neoplasms
1
Lung Diseases
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Liver Failure
1
HRD Cancer
1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
1
Drug-Related Side Effects and Adverse Reactions
1
Brain Neoplasms
1
Advanced Solid Tumors
1
Interventions
Carboplatin
71
pembrolizumab
70
Pemetrexed
62
Cisplatin
46
Nivolumab
28
Paclitaxel
27
durvalumab
26
Specimen Handling
25
osimertinib
23
Docetaxel
23
Magnetic Resonance Spectroscopy
21
Gemcitabine
17
Cetuximab
15
130-nm albumin-bound paclitaxel
15
atezolizumab
14
amivantamab
14
Radiotherapy
12
Radiosurgery
12
lazertinib
11
Ipilimumab
9
Bevacizumab
9
cemiplimab
8
Taxes
8
Drug Therapy
8
alectinib
7
Ramucirumab
7
Observation
7
Radiation
6
Leucovorin
5
Immunoglobulin G
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
sacituzumab govitecan
×
30 days
×
Clear all
NCT05633667
2026-06-01
VELOCITY-Lung
Gilead Sciences
Phase 2
Active not recruiting
192 enrolled
NCT06431633
2026-05-18
ARIAN
Fundación GECP
Phase 3
Recruiting
129 enrolled
NCT03337698
2026-05-12
Morpheus Lung
Hoffmann-La Roche
Phase 1/2
Terminated
314 enrolled
31 charts
NCT05089734
2026-05-07
EVOKE-01
Gilead Sciences
Phase 3
Active not recruiting
603 enrolled
20 charts